



# **COVID-19 Variant Surveillance Report**

Week ending August 14, 2021 (MMWR week 32)


## **Variant Surveillance- Cumulative Summary**

Lineage (WHO Classification)	Proportion of Variant Sequenced	Proportion of Variant				
	from Dec 20, 2020 (%)	Sequenced in last 4 weeks (%)				
Variant of Concern						
<b>B.1.1.7</b> (Alpha)	32.6%	0.6%				
<b>B.1.617.2</b> (Delta) <sup>§</sup>	19.0%	96.9%				
AY.2 (Delta)	0.0%	0.1%				
AY.1 (Delta)	0.0%	0.2%				
<b>P.1</b> (Gamma)	2.1%	0.5%				
<b>B.1.351</b> (Beta)	0.1%	0.0%				
Variant of Interest						
<b>B.1.526</b> (lota)	20.2%	0.0%				
B.1.526.1	2.8%	0.0%				
<b>B.1.427, B.1.429</b> (Epsilon)*	1.1%	0.0%				
<b>B.1.525</b> (Eta)	0.2%	0.0%				
<b>P.2</b> (Zeta)	0.1%	0.0%				
B.1.617	0.1%	0.0%				
<b>B.1.617.1</b> (Kappa)	0.1%	0.0%				
Other Lineages	21.7%	1.7%				
Total Number of Specimens Sequenced**	17235	2863				

<sup>§</sup> Delta includes B.1.617.2 and AY.1- AY.12 variants. As of August 23, 2021, AY.3 - AY.12 variants are aggregated with B.1.617.2.

For CDC definitions of variant of concern and variant of interest visit: https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/variant-surveillance/variant-info.html#Concern

#### **COVID-19 Variant Surveillance by Specimen Collected Week- Cumulative Summary**




Percentages represent the proportion found in the specified variant lineage. "Other" represents 158 additional lineages which include other COVID-19 variants not classified as variants of concern or variants of interest.

<sup>\*\*</sup> Includes all sequencing results reported by Commercial Labs (LabCorp, Aegis Sciences Corporation, Infinity Biologix and Quest Diagnostics) and the State Public Health Lab that have been submitted for surveillance purposes.

<sup>\*</sup>Specimens collected 8/1/2021 – 8/14/2021 reflects data for two weeks with a total of 1408 specimens.

## COVID-19 Variant Surveillance by State Region- Previous 4 weeks Summary\*



## **Variant Details**

WHO Label	Name (Pango Lineage)	First Detected	CDC Variant Classification	WHO Label
Alpha	B.1.1.7	United Kingdom	Variant of Concern	Alpha
Beta	B.1.351	South Africa	Variant of Concern	Beta
Delta	B.1.617.2, AY.1 – AY.12	India	Variant of Concern	Delta
Gamma	P.1	Brazil	Variant of Concern	Gamma
Epsilon	B.1.427, B.1.429	USA-California	Variant of Interest	Epsilon
Eta	B.1.525	USA-New York	Variant of Interest	Eta
lota	B.1.526	USA-New York	Variant of Interest	lota
	B.1.526.1	USA-New York	Variant of Interest	
Zeta	P.2	Brazil	Variant of Interest	Zeta
	B.1.617	India	Variant of Interest	
Карра	B.1.617.1	India	Variant of Interest	Карра

\*Each regional chart represents the proportion of the specified variant lineage and is based on sequencing results from the 4 weeks prior to the week of August 14, 2021. There is an approximately 14-24-day time lag between specimen collection and report of sequencing results to NJDOH. "Other" represents additional lineages which include other COVID-19 variants not classified as variants of concern or variants of interest.

Includes all sequencing results reported by Commercial Labs (LabCorp, Aegis Sciences Corporation, Infinity Biologix and Quest Diagnostics) and the State Public Health Lab that have been submitted for surveillance purposes.

Data reported is based on a subset of sampled specimens from NJ residents sequenced for COVID-19 variant surveillance.